Entia Biosciences Inc(ERGO)
USD --+0.00%
Reward44Moderate
Risk51Moderate
📊50%Data
Revenue down 33% YoY
ERGO
+0.0 · +0.00%
USD · PINK
Entia Biosciences Inc | Healthcare
Earnings Deterioration
Market Cap:10098
ℹ️
Reward Rating
44
Moderate
Bottom 25% (model universe)
50% data coverage
ℹ️
Risk Rating
51
Moderate
Risk Assessment
75% data coverage
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ERGO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Entia Biosciences Inc?

engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States.

ERGO · Verdict

Moderate reward · elevated risk

ERGO's standout is balance sheet; volatility and profitability weigh on the picture.

Based on 63% data coverage

ERGO · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet89/100

    Top decile vs peers

Watchouts 2

  • Volatility5/100

    Weak vs peers

  • Profitability10/100

    0% return on equity

Model-based scoring. For information only — not financial advice.

What is Entia Biosciences Inc?

engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 10.10K.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (44)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap10.10K
P/E RatioN/A
Dividend YieldN/A
52 Week High0.0006
52 Week Low0.0001
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding34M
No. of Employees6
IndustryBiotechnology
ExchangePINK
Beta24.642
CurrencyUSD